

Apreece, CMIC to bring 3DP pharmaceutical products to Japan

15 March 2019 | News

Apreece is the world's first and only commercial-stage manufacturer of three-dimensionally printed pharmaceuticals.



Privately held Apreece Pharmaceuticals, LLC (Apreece) and CMIC CMO Co., LTD (CMIC CMO) have announced that both companies will collaborate to develop business opportunities in Japan for Apreece's ZipDose® Technology.

CMIC CMO's services will include identifying prospects in Japan, generating awareness and facilitating discussions of technology licensing agreements, research collaborations and distribution partnerships. Through this engagement Apreece seeks to expand its 3DP products globally, and this agreement highlights the importance of Japan in its long term strategy.

Apreece is the world's first and only commercial-stage manufacturer of three-dimensionally printed pharmaceuticals. Its first 3DP innovation, ZipDose® Technology, can accommodate a wide variety of active pharmaceutical ingredients and formulation technologies to create high value products with unique performance characteristics such as rapid disintegration to better meet the needs and solve the problems of patients, caregivers and medical staff across multiple therapeutic categories. Beyond ZipDose® Technology, the company is developing additional applications for its 3DP manufacturing platform as a means to provide breakthrough products in multiple dose forms.

CMIC Group is the first and largest clinical CRO in Japan. Upon years, CMIC Group also expanded to provide comprehensive services in drug formulation development, clinical to commercial GMP manufacturing, clinical site management, regulatory consulting and contract sales.